Alyeska Investment Group L.P. purchased a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 310,287 shares of the biopharmaceutical company's stock, valued at approximately $7,850,000. Alyeska Investment Group L.P. owned about 0.18% of ACADIA Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also made changes to their positions in ACAD. Farther Finance Advisors LLC lifted its position in shares of ACADIA Pharmaceuticals by 67.5% during the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 386 shares during the last quarter. GAMMA Investing LLC grew its holdings in ACADIA Pharmaceuticals by 15.6% in the 2nd quarter. GAMMA Investing LLC now owns 2,985 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 402 shares during the last quarter. Cetera Investment Advisers increased its position in ACADIA Pharmaceuticals by 2.7% in the 4th quarter. Cetera Investment Advisers now owns 16,355 shares of the biopharmaceutical company's stock worth $437,000 after buying an additional 436 shares during the period. J.W. Cole Advisors Inc. increased its position in ACADIA Pharmaceuticals by 2.5% in the 4th quarter. J.W. Cole Advisors Inc. now owns 20,632 shares of the biopharmaceutical company's stock worth $551,000 after buying an additional 501 shares during the period. Finally, Oregon Public Employees Retirement Fund lifted its holdings in shares of ACADIA Pharmaceuticals by 2.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 28,666 shares of the biopharmaceutical company's stock worth $766,000 after buying an additional 566 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors.
Insider Buying and Selling at ACADIA Pharmaceuticals
In other news, EVP Mark C. Schneyer sold 14,292 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $29.22, for a total transaction of $417,612.24. Following the completion of the transaction, the executive vice president directly owned 67,828 shares of the company's stock, valued at approximately $1,981,934.16. This trade represents a 17.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Elizabeth H.Z. Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $26.13, for a total transaction of $432,660.54. Following the sale, the executive vice president owned 18,994 shares in the company, valued at approximately $496,313.22. This trade represents a 46.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 36,699 shares of company stock worth $1,019,894 in the last three months. Insiders own 26.20% of the company's stock.
ACADIA Pharmaceuticals Trading Down 0.7%
ACAD opened at $28.91 on Tuesday. The stock has a market cap of $4.98 billion, a PE ratio of 13.02, a P/E/G ratio of 21.71 and a beta of 0.81. ACADIA Pharmaceuticals Inc. has a 1 year low of $19.69 and a 1 year high of $30.96. The stock's 50 day simple moving average is $26.93 and its 200-day simple moving average is $23.72.
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 EPS for the quarter, beating analysts' consensus estimates of $0.07 by $0.11. The business had revenue of $308.00 million during the quarter, compared to analyst estimates of $296.55 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.ACADIA Pharmaceuticals's revenue was up 16.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.16 earnings per share. Equities analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.63 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the company. Stifel Nicolaus increased their price objective on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a "hold" rating in a research report on Tuesday, July 21st. Weiss Ratings upgraded shares of ACADIA Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a research note on Wednesday, August 12th. Citizens Jmp increased their price target on shares of ACADIA Pharmaceuticals from $35.00 to $36.00 and gave the company a "market outperform" rating in a report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft raised their price target on shares of ACADIA Pharmaceuticals from $37.00 to $38.00 and gave the stock a "buy" rating in a research report on Tuesday, August 25th. Finally, Canaccord Genuity Group upped their price objective on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a "buy" rating in a research report on Monday, June 29th. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $34.36.
Read Our Latest Report on ACAD
About ACADIA Pharmaceuticals
(
Free Report)
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.
The company's flagship product, NUPLAZID® (pimavanserin), received U.S.
Recommended Stories
Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ACADIA Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.
While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
